Biocon to meet with analysts, investors at healthcare conference

Biocon Limited, based in Bangalore, India, has scheduled a meeting with analysts and institutional investors for September 8, 2025. The company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, where interactions will be conducted in a 1x1/Group/In-Person format in New York City. This intimation is made pursuant to Regulation 30(6) of the SEBI Listing Regulations.

The company explicitly stated that it will not disclose any Unpublished Price Sensitive Information (UPSI) during the upcoming analyst/investor meeting. Biocon noted a delay in disclosing the meeting's intimation but affirmed its commitment to maintaining timely compliance with all relevant regulatory requirements. The schedule is subject to change based on the exigencies of the investors or the company.

Ekta Agarwal, interim company secretary and compliance officer, signed the announcement on September 5, 2025. The communication was addressed to the Secretaries of BSE Limited and the National Stock Exchange of India Limited.